Get the Stockscreener App
5.21
8.77%
0.42
After Hours:
5.22
0.010
+0.19%
Achieve Life Sciences Inc stock is traded at $5.21, with a volume of 1.76M.
It is up +8.77% in the last 24 hours and up +59.82% over the past month.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
See More
Previous Close:
$4.79
Open:
$4.81
24h Volume:
1.76M
Relative Volume:
1.79
Market Cap:
$534.85M
Revenue:
-
Net Income/Loss:
$-54.65M
P/E Ratio:
-4.0238
EPS:
-1.2948
Net Cash Flow:
$-49.47M
1W Performance:
+18.95%
1M Performance:
+59.82%
6M Performance:
+13.51%
1Y Performance:
+114.40%
1-Day Range:
$4.74
$5.35
1-Week Range:
$4.315
$5.35
52-Week Range:
$2.00
$6.025
Achieve Life Sciences Inc Stock (ACHV) Company Profile
Name
Achieve Life Sciences Inc
Sector
Industry
Phone
425-686-1500
Address
22722 29TH DR. SE, SEATTLE, BC
Compare ACHV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
5.21 | 534.85M | 0 | -54.65M | -49.47M | -1.2948 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Nov-25-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-21-25 | Initiated | H.C. Wainwright | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Sep-27-24 | Initiated | Raymond James | Strong Buy |
| May-10-23 | Reiterated | Maxim Group | Buy |
| Jun-23-21 | Initiated | Oppenheimer | Outperform |
View All
Achieve Life Sciences Inc Stock (ACHV) Latest News
Wall Street Zen Upgrades Achieve Life Sciences (NASDAQ:ACHV) to Sell - MarketBeat
Achieve Life Sciences Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Number of shareholders of Achieve Life Sciences, Inc. – LS:A2QAR3 - TradingView
Franklin (NYSE: ACHV) reports 6.37M-share position, includes warrants - Stock Titan
Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday - MarketBeat
Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 - The Manila Times
Achieve Life will post quarterly results before a May 12 webcast - Stock Titan
Achieve Life Sciences : Corporate Presentation April 2026 (ACHV Corporate Deck April) - marketscreener.com
MSN Money - MSN
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Canaccord Genuity initiates coverage of Achieve Life Sciences (ACHV) with buy recommendation - MSN
Achieve Life Sciences : Amendment to Annual Report (Form 10-K/A) - marketscreener.com
Board, pay and ownership details at Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan
Goodwin Advises Marshall Wace On Co-Leading Achieve Life Sciences’ $354 Million Private Placement - Mondaq
venBio Global Strategic Fund V Secures Board Seat at Achieve Life Sciences with 9.99% Stake - TradingView
venBio funds take 9.99% Achieve Life stake, add board seat (ACHV) - Stock Titan
Achieve Life Sciences (ACHV) director Royston Aaron reports zero share ownership - Stock Titan
Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering - MSN
Achieve Life Sciences announces private placement of up to $354M - MSN
Achieve Life Sciences announces proposed public offering; shares down nearly 13% - MSN
Paradigm discloses 9.2% stake in Achieve Life (NASDAQ: ACHV) - Stock Titan
TPG takes 12.6% Achieve Life Sciences (ACHV) stake via $25M structured deal - Stock Titan
TPG-affiliated holders disclose Achieve Life Sciences (NASDAQ: ACHV) shares and warrants position - Stock Titan
Achieve Life Sciences (ACHV) director files Form 3 reporting zero share ownership - Stock Titan
Frazier Life Sciences (ACHV) holds 6.5% stake; warrants disclosed - Stock Titan
Venrock entities disclose 5.2% stake in Achieve Life (ACHV) after April placement - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages - MarketBeat
Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Upgraded by Canaccord Genuity Group - MarketBeat
Achieve Life Sciences: Up To $354 Million Private Placement Funds Cytisinicline Development And Commercialization - Pulse 2.0
Achieve Life Sciences (ACHV) grants CEO large PRSU, option and RSU awards - Stock Titan
ACHIEVE LIFE SCIENCES (ACHV) CEO files Form 3 reporting zero beneficial ownership - Stock Titan
ACHV Initiates Coverage On Canaccord Genuity -- Rating Set to Bu - GuruFocus
Canaccord Genuity Initiates Coverage on Achieve Life Sciences With Buy Rating, $13 Price Target - marketscreener.com
Achieve Life Sciences flags FDA observations while pushing launch to 2027 for smoking cessation med - MSN
Bothell biotech names new CEO, looks to raise $354 million - The Business Journals
Achieve Life Sciences to Host Meetings During the J.P. Morgan He - GuruFocus
Analysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV), Decibel Cannabis Company (OtherDBCCF) and Eli Lilly & Co (LLY) - The Globe and Mail
Achieve Life Sciences secures $354M financing deal By Investing.com - Investing.com Australia
Achieve Life Sciences names new CEO, adds board members By Investing.com - Investing.com Australia
Achieve Life Sciences Raises Capital, Appoints New CEO - The Globe and Mail
Achieve Life Sciences Secures Up to $354 Million Private Placement to Advance Cytisinicline for Smoking and Vaping Cessation - Minichart
Achieve Life Sciences (ACHV) Secures $354M Through Private Place - GuruFocus
$354M funding and new CEO reshape Achieve Life Sciences (NASDAQ: ACHV) - Stock Titan
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally? - Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Achieve Life Sciences Inc Stock (ACHV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Achieve Life Sciences Inc Stock (ACHV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Oki Mark K | Chief Financial Officer |
Sep 18 '25 |
Sale |
2.92 |
50,060 |
146,175 |
127,940 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Option Exercise |
0.00 |
297,500 |
0 |
358,376 |
| Stewart Richard Alistair | Chief Executive Officer |
Sep 18 '25 |
Sale |
2.92 |
129,501 |
378,143 |
228,875 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
34,100 |
0 |
46,764 |
| Wan Jerry | Principal Accounting Officer |
Sep 04 '25 |
Sale |
2.77 |
14,070 |
38,974 |
32,694 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Option Exercise |
0.00 |
455,000 |
0 |
455,000 |
| KING THOMAS BRAXTON | Director |
Sep 04 '25 |
Sale |
2.77 |
139,858 |
387,407 |
315,142 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Option Exercise |
0.00 |
110,000 |
0 |
143,214 |
| JACOBS CINDY | President & CMO |
Sep 04 '25 |
Sale |
2.77 |
27,629 |
76,532 |
115,585 |
| Xinos Jaime | Chief Commercial Officer |
Sep 04 '25 |
Option Exercise |
0.00 |
69,000 |
0 |
95,286 |
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):